Hepatitis Forums
Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on December 09, 2019, 11:42:56 am
-
The experimental NASVAC vaccine led to a reduction in hepatitis B surface antigen (HBsAg) levels, and a small number of study participants achieved a functional cure, researchers reported at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place this week in Boston.
Approved hepatitis B prevention vaccines contain HBsAg and trigger the production of antibodies against this protein, known as anti-HBs. Although generally effective, some people do not achieve protective antibody levels. Targeting additional HBV antigens could lead to stronger immune responses that are beneficial for both prevention and treatment. An experimental prevention vaccine called Sci-Vac-B, which contains three different HBV proteins, was recently shown to offer greater protection, especially for older adults and those with weak immune systems.
For more...
https://www.hepmag.com/article/therapeutic-vaccine-help-cure-hepatitis-b